PAVmed Inc. Announces Major Business Update and Reports Q4 & Full Year 2025 Financial Results

PAVmed Inc. (NASDAQ: PAVM), a diversified commercial-stage medical technology company, has released a comprehensive business update and reported its financial results for the fourth quarter and full year ended December 31, 2025. The update includes significant strategic developments across its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) and Veris Health Inc., as well as detailed financial data that may be pivotal for investors and shareholders.

Key Highlights from the Business Update

• Strengthened Capital Structure: PAVmed completed a \$30 million Series D preferred stock offering and a \$15 million senior secured note financing. A portion of these proceeds was used to eliminate all previously outstanding convertible securities, effectively removing a legacy capital structure overhang and extending the company’s cash runway. Additionally, \$30 million in Series D warrants were issued, which are callable upon the publication of a draft CMS coverage policy for Lucid’s EsoGuard Esophageal DNA Test.
• Leadership & Portfolio Expansion: The medical device portfolio was relaunched under the leadership of industry veteran Joseph Virgilio, appointed Chief Business Officer of Medical Devices. The company’s device pipeline now includes the PortIO implantable intraosseous vascular access device and a newly licensed endoscopic esophageal imaging technology from Duke University.
• Veris Health Progress: Veris Health advanced its partnership with The Ohio State University’s James Cancer Hospital, completing full integration with the hospital’s EHR system and progressing its implantable physiological monitor towards a planned late 2026 FDA 510(k) submission.
• Lucid Diagnostics Milestones:
  • Revenue Growth: Lucid recognized \$1.5 million in revenue for Q4 2025 and processed 464 EsoGuard tests during the period.
  • VA Contract Win: Lucid secured a contract with the U.S. Department of Veterans Affairs (VA), significantly expanding access across the nation’s largest integrated healthcare system, serving approximately nine million veterans.
  • Clinical Evidence Expansion: Announced positive data from the largest real-world study of esophageal precancer detection, evaluating EsoGuard and EsoCheck devices in nearly 12,000 at-risk patients.

Detailed Financial Results

• Q4 2025 Operating Expenses: Approximately \$6.9 million, including \$0.3 million in stock-based compensation expenses.
• GAAP Net Loss (Q4 2025): Approximately \$1.8 million, or \$(2.05) per diluted share, attributable to common stockholders.
• Non-GAAP Adjusted Loss (Q4 2025): Approximately \$0.9 million, or \$(1.05) per diluted share.
• Cash Position: Cash and cash equivalents stood at \$1.5 million as of December 31, 2025, compared to \$1 million at the end of 2024.
• Full Year 2025 vs. 2024:
  • Revenue: \$71,000 (2025) vs. \$2,995,000 (2024)
  • Operating Expenses: \$21,877,000 (2025) vs. \$47,482,000 (2024)
  • Net Loss: \$2,469,000 (2025) vs. Net Income of \$28,427,000 (2024, driven by a significant gain on deconsolidation of subsidiary)
  • Net Loss Per Share (Diluted): \$(5.63) (2025) vs. \$14.90 (2024)

Key Non-GAAP Financial Measures Explained

PAVmed supplements its GAAP results with non-GAAP financial measures such as EBITDA and non-GAAP adjusted loss, which exclude stock-based compensation, gains/losses on convertible securities, and other non-cash items. This provides investors with additional insight into the company’s underlying operating performance and enhances comparability with prior periods.

Strategic and Potentially Price-Sensitive Developments

• Elimination of Convertible Securities: By settling all outstanding convertible securities, PAVmed has removed a significant dilution risk, potentially improving investor sentiment and share value.
• Callability of Series D Warrants: The issuance of \$30 million in Series D warrants—callable upon a CMS coverage policy draft for Lucid’s EsoGuard—could trigger a major capital infusion, contingent on a favorable policy from CMS, which would be a substantial catalyst for the company.
• VA Contract for EsoGuard: Winning the VA contract materially expands Lucid’s addressable market and revenue potential, positioning the company for accelerated growth if adoption rates meet expectations.
• Progress Towards FDA Submission: Veris’ advancement of its implantable physiological monitor towards a late 2026 FDA 510(k) submission represents a major pipeline opportunity and future growth driver.
• Medicare Coverage for EsoGuard: Lucid is on the cusp of potentially transformative Medicare coverage for EsoGuard, which, if granted, could dramatically increase test adoption and revenue.

Subsidiary Overviews

• Lucid Diagnostics: Focuses on early detection of esophageal precancer and cancer, primarily via the EsoGuard Esophageal DNA Test and EsoCheck Cell Collection Device. Lucid is targeting broad adoption in both VA and Medicare settings.
• Veris Health: Develops remote patient monitoring solutions for personalized cancer care, including an implantable physiological monitor intended for use alongside chemotherapy ports.

Forward-Looking Considerations

Investors should be aware of several risks and uncertainties, including regulatory approval timelines, market adoption rates for new products, and the company’s ability to secure additional funding as needed. The company also faces risks from general economic conditions, competitive developments, and fluctuations in share price.

Conclusion

PAVmed’s restructuring of its capital base, new leadership in its medical devices business, significant progress in its subsidiaries, and key contract wins collectively represent substantial progress, potentially setting up the company for accelerated growth and improved shareholder value. However, execution on regulatory, reimbursement, and commercial fronts will be critical to realizing this potential.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with their financial advisors before making any investment decisions. Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from those projected.

View PAVmed Inc. Historical chart here